Tag: Europe
-
University Offers Tuberculosis Drug Technology for Licensing
2 July 2014. A new process for developing drugs for tuberculosis designed at ETH Zurich, the Swiss Federal Institute of Technology, is offered for licensing by the university to companies for commercialization. The technology that aims to overcome resistance to many current tuberculosis drugs is the result of research from the lab of Zurich pharmaceutical…
-
Spin-Off Company Develops Drill-Less Tooth Cavity Treatment
16 June 2014. A spin-off company from Kings College London in the U.K. is developing a technology that makes treating tooth cavities a painless electrical process. Reminova Ltd. — located in Perth, Scotland — was founded earlier this year and is led by two Kings College dental faculty, Nigel Pitts and Chris Longbottom, who serve…
-
Antibody Developer Secures $40M from Foundation Investors
16 May 2014. Kymab Ltd., a developer of human antibodies from mouse genomes, raised $40 million in its second round of venture investment from the Wellcome Trust, an original backer of the company, and Bill & Melinda Gates Foundation. Kymab, based in Cambridge, U.K., is also collaborating with the Gates Foundation in research on discovery…
-
Bayer, Boehringer Ingelheim Open Clinical Trial Data
14 May 2014. Two more pharmaceutical companies, Bayer HealthCare and Boehringer Ingelheim, are making detailed data from clinical trials available to the larger scientific community. The two companies join several other pharmaceutical companies taking similar actions over the past several months. Bayer HealthCare in Leverkusen, Germany is making its trial data available through the joint industry…
-
Antioxidant-Rich Diets Fail to Reduce Heart Disease, Cancer
13 May 2014. In a study of Italians age 65 and older, researchers at Johns Hopkins University in Baltimore find people with diets high in the antioxidant resveratrol — found in berries, dark chocolate, and red wine — develop cardiac problems and cancer, and live no longer than people who consume smaller amounts. A team…
-
Immune Therapeutics Start-Up Raises $37.5M in Early Funding
6 May 2014. Anokion SA in Lausanne, Switzerland, a start-up enterprise developing therapies to treat immune systems disorders, raised 33 million Swiss francs ($US 37.5 million) in its first venture financing round. The round was led by Novartis Venture Fund, and two life-science investment companies — Novo Ventures and Versant Ventures — with participation from…
-
Genome Editing Start-Up Secures $25 Million in First Round
24 April 2014. Biopharmaceutical start-up company CRISPR Therapeutics in Basel, Switzerland raised $25 million in its first funding round. The company develops engineered gene therapies with a technology developed by one of its scientific founders, and is backed in this round by Versant Ventures, a venture capital company in Menlo Park, California. CRISPR Therapeutics’ technology…
-
Intelligent Liner Aims to Improve Prosthetic Limb Comfort
15 April 2014. Engineers in the U.K. at University of Southampton and Chas A Blatchford & Son Ltd. in Basingstoke are designing a liner with sensors for lower-limb prosthetic devices that improve the fit and comfort of those devices for their wearers. The team is developing a prototype device that they aim to have available…
-
MRSA Toxicity Predicted Through Genomic Sequencing
9 April 2014. Researchers in the U.K., U.S., Sweden, and Turkey developed a technique based on genomic sequencing to predict the pathogenic severity of methicillin resistant Staphylococcus aureus or MRSA bacteria, an antibiotic-resistant microbe often found in health care facilities. The team led by University of Bath biologist Ruth Massey published its findings today online…
-
University, Board Maker Partner on Point-of-Care Diagnostics
8 April 2014. Computer scientists in the U.K. at Southampton University and circuit board manufacturer Newbury Electronics Ltd. are designing a device to detect protein indicators for diagnosing diseases at a doctor’s office or clinic rather than sending out samples to a lab for analysis. The three-year project led by Southampton’s Themis Prodromakis, is funded…